| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, Dibenzyl aspartate 4-methylbenzenesulfonate functions as a chemical tool rather than a pharmacologically active drug; thus, its "target" is the peptide bond formation process in synthetic chemistry. The compound itself does not target specific biological receptors or enzymes in the classical pharmacological sense. Instead, it serves as a protected aspartic acid derivative for incorporation into peptide chains via selective deprotection and coupling reactions. The benzyl ester protecting groups on both carboxylates enable orthogonal deprotection strategies, allowing for controlled peptide assembly. The tosylate salt form provides enhanced stability and handling characteristics compared to other salt forms. Substituting this compound with seemingly similar alternatives, such as the hydrochloride salt or other protected aspartic acid derivatives, can critically undermine synthesis outcomes due to differences in crystallinity, solubility, and stability.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Dibenzyl aspartate 4-methylbenzenesulfonate is evaluated primarily through its performance in peptide coupling reactions rather than biological assays. In standard peptide synthesis, the compound demonstrates high coupling efficiency when used as a protected aspartic acid building block. The benzyl ester protecting groups provide stability under standard peptide coupling conditions and can be removed by hydrogenolysis. Quality control assessments include HPLC purity analysis (typically ≥98%) and characterization by NMR and mass spectrometry. The compound shows no intrinsic biological activity in cell-free systems as it is strictly a synthetic intermediate. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements, influencing the release of anabolic hormones and fuel availability during activity. |
| ln Vivo |
In vivo activity is not applicable to Dibenzyl aspartate 4-methylbenzenesulfonate as this compound is not intended for administration to living organisms. It is exclusively a research chemical and synthetic intermediate used in laboratory settings for peptide preparation. The compound is not designed for therapeutic or diagnostic purposes in animal models. Any biological activity that might be observed would be a result of metabolic conversion following deprotection, but such studies are not typically conducted with this protected amino acid derivative. Its utility lies entirely in the chemical synthesis domain rather than in pharmacological evaluation. The compound is stored and handled under standard laboratory conditions for chemical synthesis, protected from light. No established animal models or in vivo efficacy studies exist for this compound.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Dibenzyl aspartate 4-methylbenzenesulfonate involves standard peptide synthesis and characterization procedures. A typical workflow: dissolve the compound (1.0 equivalent) in an appropriate solvent such as DMF or DCM, activate the carboxylic acid (if needed) using standard coupling reagents such as HATU or DCC along with a base (e.g., DIEA), then add the amine component. The reaction mixture is stirred at room temperature for 1-4 hours, and progress is monitored by TLC. After completion, the product is isolated by extraction and purified by column chromatography or recrystallization. Characterization includes ¹H-NMR, ¹³C-NMR, and mass spectrometry to confirm structure. HPLC purity (typically ≥98%) is used for quality control. The compound's solubility in DMSO, DMF, and other organic solvents facilitates its use in homogeneous reaction conditions.
|
| Cell Assay |
In vitro cell-based experimental workflows are not typically performed with Dibenzyl aspartate 4-methylbenzenesulfonate, as the compound is not intended for biological activity screening. However, when used as a precursor in peptide synthesis, the resulting deprotected peptides may be subjected to cell-based assays. In such cases, the compound would first be deprotected to liberate the free aspartic acid-containing peptide, and the final peptide product would be tested in appropriate cell lines. Typical assays might include cell viability (MTT assay), apoptosis detection (Annexin V staining), or receptor binding studies depending on the biological target of the synthesized peptide. Cells are typically cultured in DMEM with 10% FBS, treated with peptide concentrations ranging from 0.1 to 100 µM for 24-72 hours, and read by plate reader or flow cytometry. The protected amino acid derivative itself is not directly tested in these systems.
|
| Animal Protocol |
In vivo animal experimental workflows are not applicable to Dibenzyl aspartate 4-methylbenzenesulfonate. This compound is exclusively a synthetic intermediate and research chemical, not a drug candidate intended for animal testing. There are no established animal models or in vivo protocols associated with this protected amino acid derivative. Any in vivo studies would involve the final deprotected peptide products rather than the protected intermediate itself. The compound is stored and handled under standard laboratory conditions for chemical synthesis, protected from light. Industrial production follows optimized synthetic routes ensuring enantiopurity, with the tosylate salt form providing consistent hydrogenolysis deprotection kinetics across stereoisomers.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Dibenzyl aspartate 4-methylbenzenesulfonate have not been characterized, as the compound is not intended for pharmaceutical use. Being a protected amino acid derivative with a molecular weight of 485.55 g/mol and LogP of approximately 1.07, it would be expected to have moderate lipophilicity if it were administered. However, the benzyl ester protecting groups would likely be cleaved metabolically, and any pharmacokinetic data would pertain to the liberated aspartic acid rather than the parent compound. The compound is stable under recommended storage conditions (powder at -20°C for 3 years, 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month) and is not designed for systemic exposure in living organisms. No data on absorption, distribution, metabolism, or excretion are available for the protected form. The compound is stable at ambient temperature for a few days during ordinary shipping.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dibenzyl aspartate 4-methylbenzenesulfonate are limited as it is not a pharmaceutical agent. Standard safety precautions apply when handling this chemical: it may cause skin and eye irritation, and inhalation of dust should be avoided. The compound should be handled in a fume hood with appropriate personal protective equipment including gloves, safety glasses, and laboratory coat. No chronic toxicity, carcinogenicity, or reproductive toxicity studies have been conducted, as these are not relevant for a synthetic intermediate. The compound is intended for research use only and is not approved for human or veterinary applications. It is not classified as a hazardous substance under most regulatory frameworks, but standard laboratory chemical safety practices should be followed.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Dibenzyl aspartate 4-methylbenzenesulfonate is a well-established reagent in peptide chemistry, serving as a key intermediate for the preparation of enantiomerically pure building blocks and complex peptides. It is an aspartic acid analogue and amino acid derivative. The compound is commercially available from multiple suppliers and is typically offered with purity ≥98%. It is not a drug and has not undergone clinical trials or received regulatory approval. The compound's p-toluenesulfonate counterion directly influences its crystallinity, melting point, solubility profile, and stability, all of which are essential for predictable handling, purification, and reaction performance. The optimized synthetic route ensures enantiopurity-validated against alternative solvents that produce racemic mixtures. The compound is available in various pack sizes for research applications.
|
| Molecular Formula |
C25H27NO7S
|
|---|---|
| Molecular Weight |
485.55
|
| Exact Mass |
485.15
|
| CAS # |
4079-62-3
|
| PubChem CID |
353536
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
455.3ºC at 760 mmHg
|
| Flash Point |
180.6ºC
|
| LogP |
5.213
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C(C=C1)COC(=O)CC(C(=O)OCC2=CC=CC=C2)N
|
| InChi Key |
HLMUYZYLPUHSNV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H19NO4.C7H8O3S/c19-16(18(21)23-13-15-9-5-2-6-10-15)11-17(20)22-12-14-7-3-1-4-8-14;1-6-2-4-7(5-3-6)11(8,9)10/h1-10,16H,11-13,19H2;2-5H,1H3,(H,8,9,10)
|
| Chemical Name |
dibenzyl 2-aminobutanedioate;4-methylbenzenesulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0595 mL | 10.2976 mL | 20.5952 mL | |
| 5 mM | 0.4119 mL | 2.0595 mL | 4.1190 mL | |
| 10 mM | 0.2060 mL | 1.0298 mL | 2.0595 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
